An observational study in Multiple Sclerosis, sponsored by University Hospital, Lille. Recruiting at 1 site in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by University Hospital, Lille · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Multiple Sclerosis by University Hospital, Lille — 4 open to participants now, 4 under way, none of them phase 3. Multiple Sclerosis · University Hospital, Lille.
Among the 11 studies in Multiple Sclerosis by University Hospital, Lille, this one is the only one that started in 2026, is one of 7 observational ones, and was the 11th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →4 of the 11 studies in Multiple Sclerosis by University Hospital, Lille are open now, in 1 country. Recruiting first, the newest first:
University Hospital, Lille · Sites in France
Ages 18–55
University Hospital, Lille · Sites in France
Ages 18–65
University Hospital, Lille · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 115 is above the median of 100 across 972 observational studies indexed under Multiple Sclerosis.
Median enrollment 134 across the 4 interventional studies, 115 across the 7 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Lille is the lead sponsor of 631 studies on the registry; 142 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Multiple Sclerosis by University Hospital, Lille, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This real-life study aims to describe IgG levels after switching from ocrelizumab 600 mg IV every 6 to 8 months in Patients with Multiple Sclerosis (PwMS) to ofatumumab 20 mg SC every month and showing a decreasing level of IgG during treatment by ocrelizumab in real life practice in France over 24 months of follow-up.
The primary objective is therefore to determine if the downward trend of IgG observed during ocrelizumab treatment is modified after a switch to ofatumumab, in PwMS treated during at least 18 months of ocrelizumab in real life practice, over 24 months of follow-up.
time perspective: retrospective and prospective
The study population will be adult patients with MS (women and men) who initiate treatment with ofatumumab after a treatment with ocrelizumab
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Able to provide their non-opposition
Exclusion Criteria:
Adult patients (≥18 years) with relapsing multiple sclerosis treated with ocrelizumab for at least 18 months and already switched or switching from ocrelizumab to ofatumumab treatment
Drug: ofatumumab
There is no treatment allocation. Participants with MS that initiated treatment with ofatumumab (Kesimpta ®) as per neurologist practice and regardless of the study protocol.
Slope of serum immunoglobulin G (IgG) levels during ocrelizumab treatment period (minimum 18 months)
Time frame: 42 months
Slope of serum immunoglobulin G (IgG) levels during ofatumumab treatment period (24 months)
Time frame: 42 months
Age at baseline (years)
Time frame: Baseline
Number and percentage of patients with stable serum IgG levels
Time frame: 24 months
Number of severe infections occurring during ocrelizumab treatment period prior to switch to ofatumumab
Time frame: 18 months
Slope of serum immunoglobulin M (IgM) levels during ocrelizumab treatment period (minimum 18 months)
Time frame: 24 months
Distribution of Expanded Disability Status Scale (EDSS) scores after switch to ofatumumab
Expanded Disability Status Scale (EDSS): score range 0-10, where higher scores indicate greater neurological disability (worse outcome).
Time frame: 24 months
Number of patients who discontinued ofatumumab before the end of follow-up
Time frame: 24 months
Number and type of adverse events (AEs) during ofatumumab follow-up period
Time frame: 24 months
Disease duration (years since diagnosis)
Time frame: Baseline
Sex distribution (male/female, percentage of patients)
Time frame: Baseline
Number and percentage of patients with increased serum IgG levels
Time frame: 24 months
Slope of serum immunoglobulin M (IgM) levels during ofatumumab treatment period (24 months)
Time frame: 24 months
Distribution of Fatigue Severity Scale (FSS) scores after switch to ofatumumab
Fatigue Severity Scale (FSS): score range 9-63, where higher scores indicate greater fatigue severity (worse outcome).
Time frame: 24 months
Distribution of Multiple Sclerosis Functional Composite (MSFC) scores after switch to ofatumumab
Multiple Sclerosis Functional Composite (MSFC): standardized composite score (z-score), with higher scores indicating better neurological function (better outcome).
Time frame: 24 months
Number of relapses per patient after switch to ofatumumab
Time frame: 24 months
Reasons for discontinuation of ofatumumab before the end of follow-up
Time frame: 24 months
Number and type of serious adverse events (SAEs) during ofatumumab follow-up period
Time frame: 24 months
Started Oct 2026 (actual). Primary completion is estimated for Jun 2029, 32 months after the start.
Of 336 non-industry observational studies under Multiple Sclerosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 81. This study's planned 32 months is below that.
Counting every sponsor, half of 427 studies reached it within 41 months; a quarter within 15 and three quarters within 75.
Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Oct 2026, on Oct 30, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.